Rapid responses are electronic comments to the editor. They enable our users
to debate issues raised in articles published on bmj.com. A rapid response
is first posted online. If you need the URL (web address) of an individual
response, simply click on the response headline and copy the URL from the
browser window. A proportion of responses will, after editing, be published
online and in the print journal as letters, which are indexed in PubMed.
Rapid responses are not indexed in PubMed and they are not journal articles.
The BMJ reserves the right to remove responses which are being
wilfully misrepresented as published articles or when it is brought to our
attention that a response spreads misinformation.
From March 2022, the word limit for rapid responses will be 600 words not
including references and author details. We will no longer post responses
that exceed this limit.
The word limit for letters selected from posted responses remains 300 words.
The Institute of Clinical Research broadly supports the joint
position statement issued by four major Associations representing the
pharmaceutical industry on 6th January 2005.
This important move towards transparency in clinical research will
play a vital role in improving public confidence in the professionalism
and diligence of the clinical research community, and will also enable
professionals to avoid unwittingly duplicating earlier studies. The
Institute of Clinical Research is keen to support measures that
demonstrate and underpin high professional standards in the design,
conduct and publication of all forms of clinical research.
The majority of commercial organisations sponsoring clinical trials
on pharmaceuticals are party to this statement as members of their
relevant Associations. However, clinical research around the world is also
sponsored by other bodies (including charities, government and healthcare
providers). The Institute of Clinical Research calls for all these other
sponsoring bodies to consider adopting a similar position with regard to
publication of study initiation and results. Only in this way will the
clinical research community as a whole demonstrate to the public its
commitment to the highest standards of professionalism and transparency.
Competing interests:
None declared
Competing interests:
No competing interests
14 January 2005
Andrew M Smith
Editor, Clinical Research focus, The Institute of Clinical Research
Broad support from the Institute of Clinical Research, but other sponsors should follow suit
The Institute of Clinical Research broadly supports the joint
position statement issued by four major Associations representing the
pharmaceutical industry on 6th January 2005.
This important move towards transparency in clinical research will
play a vital role in improving public confidence in the professionalism
and diligence of the clinical research community, and will also enable
professionals to avoid unwittingly duplicating earlier studies. The
Institute of Clinical Research is keen to support measures that
demonstrate and underpin high professional standards in the design,
conduct and publication of all forms of clinical research.
The majority of commercial organisations sponsoring clinical trials
on pharmaceuticals are party to this statement as members of their
relevant Associations. However, clinical research around the world is also
sponsored by other bodies (including charities, government and healthcare
providers). The Institute of Clinical Research calls for all these other
sponsoring bodies to consider adopting a similar position with regard to
publication of study initiation and results. Only in this way will the
clinical research community as a whole demonstrate to the public its
commitment to the highest standards of professionalism and transparency.
Competing interests:
None declared
Competing interests: No competing interests